When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Leprosy

Última revisão: 15 Jun 2025
Última atualização: 10 Nov 2022

Resumo

Definição

História e exame físico

Principais fatores diagnósticos

  • typical skin lesions
  • nerve involvement
  • sensory loss
Detalhes completos

Outros fatores diagnósticos

  • immunologic reactions
  • eye lesions
Detalhes completos

Fatores de risco

  • close contact with a person with multibacillary leprosy
  • poverty
  • residence in endemic area
  • genetic predisposition
  • zoonotic transmission
Detalhes completos

Investigações diagnósticas

Primeiras investigações a serem solicitadas

  • skin smear
  • skin and/or nerve biopsy and histopathology
Detalhes completos

Investigações a serem consideradas

  • polymerase chain reaction
Detalhes completos

Algoritmo de tratamento

AGUDA

multibacillary (MB) or paucibacillary (PB): no rifampin or fluoroquinolone resistance

multibacillary (MB) or paucibacillary (PB): rifampin ± fluoroquinolone resistance

CONTÍNUA

type 1 reaction (reversal reaction)

type 2 reaction (erythema nodosum leprosum)

Lucio phenomenon

Colaboradores

Autores

Maria T. Ochoa, MD

Clinical Professor of Dermatology

USC Keck School of Medicine

Department of Dermatology

Los Angeles

CA

Declarações

MTO declares that she has no competing interests.

Agradecimentos

Dr Maria T. Ochoa would like to gratefully acknowledge Dr Denis Paul Jacques Daumerie, a previous contributor to this topic. DPJD declares that he has no competing interests.

Revisores

Hubert Sansarricq, MD

Member of World Health Organization Panel of Experts on Leprosy

Saint-Armour Morlaas

France

Declarações

HS declares that he has no competing interests.

David M. Scollard, MD, PhD

Chief

Clinical Branch

National Hansen's Disease Programs

Baton Rouge

LA

Declarações

DMS declares that he has no competing interests.

Alexandre Tiendrebéogo, MD, MPH

Medical Officer

Leprosy and Neglected Tropical Diseases in Central Africa Countries

World Health Organization

Country Office of Kinshasa

DR of Congo

Declarações

AT declares that he has no competing interests.

Referências

Nossas equipes internas de editoria e de evidências trabalham em conjunto com colaboradores internacionais especializados e pares revisores para garantir que forneçamos acesso às informações o mais clinicamente relevantes possível.

Principais artigos

World Health Organization. Towards zero leprosy. Global leprosy (Hansen’s Disease) strategy 2021-2030. Apr 2021 [internet publication].Texto completo

World Health Organization. Implementation of MDT. In: Multidrug therapy against leprosy: development and implementation over the past 25 years. Geneva: World Health Organization; 2004:45-68.Texto completo

World Health Organization. Guidelines for the diagnosis, treatment and prevention of leprosy. Oct 2018 [internet publication].Texto completo

World Health Organization. Leprosy/Hansen disease: management of reactions and prevention of disabilities. 2020 [internet publication].Texto completo

Artigos de referência

Uma lista completa das fontes referenciadas neste tópico está disponível para os usuários com acesso total ao BMJ Best Practice.
  • Leprosy images
  • Diagnósticos diferenciais

    • Psoriasis
    • Eczema
    • Tinea corporis
    Mais Diagnósticos diferenciais
  • Diretrizes

    • Towards zero leprosy. Global leprosy (Hansen’s Disease) strategy 2021-2030
    • Leprosy/Hansen disease: contact tracing and post-exposure prophylaxis
    Mais Diretrizes
  • padlock-lockedConectar-se ou assinar para acessar todo o BMJ Best Practice

O uso deste conteúdo está sujeito ao nosso aviso legal